Eye Cancer Treatment Market 2025: Industry Developments, Future Growth, Share & Industry Insights | Novartis AG, Spectrum Pharmaceuticals, Inc, GlaxoSmithKline plc, Bayer AG, Amgen ,Takeda Pharmaceuticals

Eye Cancer Treatment Market is expected to reach at a CAGR of 7% during the forecast period 2024-2031.

DataM Intelligence has published a new research report on "Eye Cancer Treatment Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/eye-cancer-treatment-market?sg

Key Players: Novartis AG, Spectrum Pharmaceuticals, Inc, GlaxoSmithKline plc, Bayer AG, Amgen ,Inc ,Takeda Pharmaceuticals Company Limited ,Eli Lilly and Company, AstraZeneca, F. Hoffmann -La Roche Ltd, Janssen Global Services, LLC , Sanofi ,Abbvie, Inc, Pfizer.Inc, Merck & Co, Inc.

United States - Industry Latest News:

✅ FDA Approves Epioxa for Keratoconus
On October 20, 2025, the FDA approved Epioxa, the first treatment for keratoconus that does not require removal of the corneal epithelium.

✅ IDEAYA Biosciences Presents Phase 2 Data for Darovasertib
On October 20, 2025, IDEAYA Biosciences announced positive Phase 2 data for darovasertib in the neoadjuvant setting of primary uveal melanoma at ESMO 2025.

✅ Alcon Completes Acquisition of LumiThera
On September 2, 2025, Alcon completed the acquisition of LumiThera, adding the FDA-approved Valeda system for noninvasive dry AMD therapy to its retina portfolio.

✅ McKesson Acquires Controlling Interest in PRISM Vision Holdings
On February 4, 2025, McKesson announced the acquisition of an 80% interest in PRISM Vision Holdings, enhancing its specialty ophthalmology services.

Japan - Industry Latest News:

✅ Rakuten Medical Advances Photoimmunotherapy
On July 28, 2025, Rakuten Medical announced progress in its photoimmunotherapy for eye cancer, currently investigational outside Japan.

✅ Celltrion Receives FDA Approval for Eydenzelt Biosimilar
On October 21, 2025, Celltrion received FDA approval for Eydenzelt, a biosimilar to Eylea, expanding its ophthalmic portfolio.

South Korea - Industry Latest News:

✅ Ocugen and Kwangdong Complete License Agreement for OCU400
On September 15, 2025, Ocugen and Kwangdong Pharmaceutical finalized a license agreement for OCU400 gene therapy for retinitis pigmentosa in Korea.

✅ KDDF Hosts Immuno-Oncology Therapy Workshop
On August 8, 2025, the Korea Drug Development Fund hosted a workshop on the latest trends in immuno-oncology therapy, focusing on joint R&D initiatives.

Europe - Industry Latest News:

✅ Lupin Acquires VISUfarma to Expand Ophthalmology Portfolio
On September 29, 2025, Lupin announced the acquisition of VISUfarma, enhancing its global specialty ophthalmology business with over 60 branded ophthalmology products.

✅ Tebentafusp Approved for Uveal Melanoma in the UK
On December 3, 2024, the UK's NHS approved tebentafusp for treating uveal melanoma, marking the first treatment of its kind for this rare eye cancer.

Growth Forecast Projected:

The Global Eye Cancer Treatment Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Eye Cancer Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=eye-cancer-treatment-market?sg

Key Segments:

By Treatment (Brachytherapy, External Radiotherapy, Enucleation, Chemotherapy, Others)

By Drugs (Pembrolizumab, Ipilimumab, Dacarbazine, Temozolomide, Others)

By Type (Eye melanoma, Squamous cell carcinoma, Retinoblastoma, Rhabdomyosarcoma)

By Route of Administration(Oral, Intravenous, Tropical, Others)

By End User(Hospital, Clinics, Cancer centers, Diagnostic centers, Ambulatory surgical centers)

By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Eye Cancer Treatment producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Eye Cancer Treatment revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/eye-cancer-treatment-market?sg

FAQ's

Q1: Which regions are dominating the Eye Cancer Treatment market and which are fastest-growing?

A: North America region holds the largest market share of global eye cancer treatment market.

Q2: How fast is the Eye Cancer Treatment Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 7% from 2024-2031.

Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/eye-cancer-treatment-market?sg

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.